<div id="readability-page-1"><div><p>Axogen (AXGN) opened 2026 with Q1 revenue of US$61.5 million and a basic EPS loss of US$0.38, alongside a net loss of US$19.6 million. This keeps the focus firmly on how fast the top line can support a path back toward profitability. Over the past five reported quarters, revenue has moved from US$48.6 million in Q1 2025 to US$61.5 million in Q1 2026, while basic EPS has swung between a small profit of US$0.02 and losses, including US$0.08 in Q1 2025 and US$0.38 this quarter. In that context, the latest numbers put the spotlight on whether Axogen can pull more operating leverage from its sales base and start closing the gap in its margins.</p> <p>See our full analysis for Axogen.</p><p>With the headline figures on the table, the next step is to line these results up against the most common Axogen narratives to see which stories the numbers support and which ones start to look overstretched.</p> <p>See what the community is saying about Axogen</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4816cb58-09b6-4bdf-b220-cdddbec02503/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4816cb58-09b6-4bdf-b220-cdddbec02503/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI5"/><figcaption>NasdaqCM:AXGN Revenue &amp; Expenses Breakdown as at Apr 2026</figcaption></figure> <h2>Losses widen again on trailing numbers</h2> <ul> <li>On a trailing 12 month basis, Axogen reported total revenue of US$238.1 million and a net loss of US$31.5 million, compared with US$225.2 million of revenue and a US$15.7 million loss for the prior trailing period.</li> <li>Consensus narrative expects expanding market adoption and better margins over time, yet the latest trailing figures still show earnings in the red, which creates a tension between:     <ul> <li>Forecasts that earnings could grow strongly with a path to profitability within three years, while the most recent trailing EPS is a loss of US$0.66 per share.</li> <li>The idea of improving operational leverage, set against net losses that have widened on the latest 12 month view compared with the prior trailing period.</li> </ul> </li> </ul> <h2>Quarterly swing from small profit to larger loss</h2> <ul> <li>Q1 2026 net loss was US$19.6 million on revenue of US$61.5 million, compared with Q3 2025 net income of US$0.7 million on US$60.1 million of revenue and Q4 2025 net loss of US$13.2 million on US$59.9 million of revenue.</li> <li>Bullish views highlight potential for better operating leverage as sales build, yet the recent pattern of quarterly results raises questions about how smooth that path might be, because:     <ul> <li>Profitability flipped from a small profit in Q2 and Q3 2025, with EPS of about US$0.01 per share in each of those quarters, to losses again in Q4 2025 and Q1 2026, including a Q1 2026 loss of US$0.38 per share.</li> <li>The move from roughly breakeven to a larger quarterly loss suggests the margin profile is still sensitive even at revenue levels around US$60 million per quarter.</li> </ul> </li> </ul><p> Curious how this earnings swing fits into the bullish case that highlights margin improvement and long term growth potential, and see how supporters frame the upside in spite of the latest loss print: <strong>🐂 Axogen Bull Case</strong>. </p><h2>Rich multiples versus DCF fair value</h2> <ul> <li>At a share price of US$41.99 and a P/S of 9.2x compared with peers at 4.7x and the US Medical Equipment industry at 2.9x, the stock also sits above a cited DCF fair value of about US$32.01 per share.</li> <li>Bearish arguments focus on valuation and dilution, and the current data provide clear support for that caution, because:     <ul> <li>Shareholders have already seen their ownership diluted over the past year, which matters more when the company is still loss making on both the latest quarter and the trailing 12 month figures.</li> <li>The gap between the current price and the DCF fair value, alongside higher P/S multiples than peers and the broader industry, underpins concerns that a lot of the projected growth is already reflected in the valuation.</li> </ul> </li> </ul><p> If you are weighing whether these rich multiples leave enough room for error, it can help to see how skeptics frame the downside case around valuation and dilution: <strong>🐻 Axogen Bear Case</strong></p><h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Axogen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>Given the mix of optimism and concern running through these results, it is worth checking the underlying data yourself and forming your own view. This includes weighing up the company's 1 key reward and 1 important warning sign</p> <h2>Explore Alternatives</h2> <p>Axogen is still reporting losses on both a quarterly and trailing 12 month basis while trading on richer multiples than peers and a cited DCF value.</p> <p>If that combination of widening losses and a full valuation feels like too much risk, it is worth scanning companies in the 72 resilient stocks with low risk scores that aim for more resilient profiles.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

AXGN

<p>Axogen (AXGN) reported Q1 2026 revenue of US$61.5 million with a basic EPS loss of US$0.38, widening its net loss to US$19.6 million. Despite a revenue increase from US$48.6 million in Q1 2025, the company struggles with profitability, showing a net loss of US$31.5 million over the trailing 12 months. The stock trades at a high P/S ratio of 9.2x, raising concerns about valuation and dilution amidst ongoing losses. Investors are advised to consider the balance of optimism and caution in Axogen's financial outlook.</p>

Axogen (AXGN) Q1 Loss Of US$0.38 EPS Tests Bullish Margin Improvement Narrative